

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)					ATTY. DOCKET NO. 4821-306		APPLICATION NO. 09/029,260	
					APPLICANT MCCULLOUGH, J.R. et al.			
					FILING DATE March 16, 1998		GROUP Art Unit 1614 1623	
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
me	1.	4,777,170	10/11/88	Heinrich	514	226.2		
me	2.	3,940,485	2/24/76	Levinson et al.	514	255.000		
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
me	3. !	Petrin, A., 1974, "Motion Sickness and its Treatment", <i>Schweiz. Med.</i> 63:79-81.						
me	4.	Wood, C.D. et al., 1987, "Mechanisms of Antimotion Sickness Drugs", <i>Aviation, Space, and Envir. Med.</i> pp. A262-A265. (September, 1987).						
EXAMINER L. E. Crane <i>[Signature]</i>								
DATE CONSIDERED					06/09/99			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

! Month of publication data is unavailable for this reference.

RECEIVED
SEP 17 1999
GROUP 1800

COPY FOR ☒ File ☐ Applicant



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

4821-306

SERIAL NO.

09/039,260

APPLICANT

McCullough, J.R. et al.

FILING DATE

March 16, 1998

GROUP Art Unit

1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Me	AA	5,089,496	2/18/92	Piwinski et al.	514	253.000	
Me	AB	5,019,591	5/28/91	Gardner et al.	514	461.000	
Me	AC	4,659,716	4/21/87	Villani et al.	514	290/000	
Me	BN	5,595,997	1/21/97	Aberg et al.	514	290.000	
Me	BO	4,282,233	8/4/81	Villani	514	290.000	
Me	BP	4,008,796	2/22/77	Aylon	198	460.100	
Me	BQ	3,598,123	8/10/71	Zaffaroni	424	435.000	
Me	BR	3,536,809	10/27/70	Applezweig	424	435.000	

FOREIGN PATENT DOCUMENTS




		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
Me	AD	WO 92/11034	07/09/92	PCT	-----	-----		
Me	AE	WO 92/00293	09/01/92	PCT	-----	-----		
Me	AF	O 288 640	11/02/88	EPA	-----	-----		
Me	AG	WO 85/03707	08/29/85	PCT	-----	-----		
Me	BS	WO 96/20708	7/11/96	PCT	-----	-----		
Me	BT	WO 92/20377	11/26/92	PCT	-----	-----		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

**	AH	Babe et al., 1996, "Histamine, Bradykinin, and Their Antagonists", Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 581-593 and 598-599
**	AI	McCue, J., 1996, "Safety of Antihistamines in the Treatment of Allergic Rhinitis in Elderly Patients", Arch. Fam. Med. 5:464-468

**	AJ	Andersen et al., 1995, "Adverse Drug Interactions Clinically Important for the Dermatologist", Arch. Dermatol. <u>131</u>:468-473
**	AK	Peggs et al., 1995, "Antihistamines. The Old and The New", American Family Physician <u>52(2)</u>:593-600
**	AL	Berthon et al., 1994, "In Vitro Inhibition, by Loratadine and Descarboxyethoxloratadine, of Histamine Release from Human Basophils, and of Histamine Release and Intracellular Calcium Fluxes in Rat Basophilic Leukemia Cells (RBL-2H3)", Biochemical Pharmacology <u>47(5)</u>: 789-794
**	AM	Brandes et al., 1994, "Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H₁-Antihistamines: Predictive In Vitro Correlates", J. Nat. Can. Inst. Reports <u>86(10)</u>: 770-775
**	AN	Kleine-Tebbe et al., 1994, "Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H₁-antagonist, desethoxycarbonyl-loratadine", J. Allergy Clin. Immunol. <u>93(2)</u>:494-500
**	AO	Miadonna et al., 1994, "Inhibitory Effect of the H₁ Antagonist Loratadine on Histamine Release from Human Basophils", Int. Arch. Allergy Immunol. <u>105</u>:12-17
**	AP	Simons, F.E.R., 1994, "H₁ Receptor Antagonists Comparative Tolerability and Safety", Drug Safety <u>10(5)</u>:350-380
**	AQ	Zhong et al., 1994, "HPLC Bestimmung Von Loratadin und seinem aktiven Metaboliten Descarboethoxyloratadin in Humanplasma", Pharmazie <u>49(10)</u>:736-739 (English abstract attached)
**	AR	Queroia et al., 1993, "<u>Focus on loratadine</u>: A new second-generation nonsedating H₁-receptor antagonist", Hosp. Formul. <u>28</u>:137-149, 153
**	AS	Lavrijsen et al., 1993, "The Interaction of Ketoconazole, Itraconazole and Erythromycin With the In Vitro Metabolism of Antihistamines in Human Liver Microsomes", Abstract 1233 Eur. J. Allergy Clin. Immunol. <u>48(Suppl. 16)</u>:34
**	AT	Roman et al., 1993, "Loratadine - A Review of Recent Findings in Pharmacology, Pharmacokinetics, Efficacy, and Safety, with a Look at Its Use in Combination with Pseudoephedrine", Clinical Reviews in Allergy <u>11</u>:89-110
**	AU	Van Peer et al., 1993, "Ketoconazole Inhibits Loratadine Metabolism in Man", Abstract 1234 Eur. J. Allergy Clin. Immunol. <u>48(Suppl. 16)</u>:34
**	AV	Product Insert CR-318/17597400 7/93 Schering Corporation (1992, 1993)
**	AW	Brandes et al., 1992, "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses", Cancer Research <u>52</u>:3796-3800
**	AX	Kaliner, M., 1992, "Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects", American Family Physician <u>45(3)</u>:1337-1342

**	AY	Knowles, 1992, "Astemizole and Terfenadine - Induced Cardiovascular Effects", Canadian J. Hosp. Pharm. <u>45(1)</u> :33, 37
**	AZ	Parkinson et al., 1992, "Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 In Rats and Mice", Biochemical Pharmacology <u>43(10)</u>:2169-2180
**	BA	Van Cauwenberge, P., 1992, "New Data on the Safety of Loratadine", Drug Invest. <u>4(4)</u>:283-291
**	BB	Barnett et al., 1991, "Pharmacology of Non-Sedating H₁ Antihistamines", New Perspectives in Histamine Research pp. 181-196
**	BC	"Antihistamines", 1990, Chapter 16 Side Effects of Drugs Annual <u>14</u>:135-138 Elsevier Science Publishers
**	BD	Gengo, F.M., 1990, "Dilemma: Antihistamine Selection: Use vs. Side Effects", U.S. Pharmacist pp. 59-72, 92
**	BE	Clissold et al., 1989, "Loratadine A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy", Drugs <u>37</u>:42-57
**	BF	"Antihistamines", 1988, Chapter 16 Side Effects of Drugs Annual <u>12</u>:142-143 Elsevier Science Publishers
**	BG	Simons et al., 1988, "Astemizole Induced Torsades de Pointes", Lancet p. 624
**	BH	Temple et al., 1988, "Loratadine, an Antihistamine, Blocks antigen- and Ionophore - Induced Leukotriene Release From Human Lung In Vitro", Prostaglandins <u>35(4)</u>:549-554
**	BI	Hilbert et al., 1987, " Pharmacokinetics and Dose Proportionality of Loratadine", J. Clin. Pharmacol. <u>27</u>:694-698
**	BJ	Craft, 1986, "Torsade de Pointes After Astemizole Overdose", British Med. J. <u>292</u>:660
**	BK	Barnett et al., 1984, " Evaluation of the CNS properties of SCH-29851, a potential non-sedating antihistamine", Agents and Actions <u>14(5/6)</u>:590-597
**	BL	Wood, 1979, "Antimotion Sickness and Antiemetic Drugs", Drugs <u>17(17)</u>:471-479
**	BM	Cohen et al., 1972, "Meclizine and Placebo in Treating Vertigo of Vestibular Origin", Arch. Neurol. <u>27</u>:129-135
<i>He</i>	BU!	Goodman and Gilman's, 1996, <u>The Pharmacological Basis of Therapeutics</u> , 9th Ed. p. 148, 588-592
<i>He</i>	BV!	Carmeliet, 1992, "Voltage- and Time-Dependent Block of the Delayed K ⁺ Current in Cardiac Myocytes by Dofetilide", J. Pharmacol. Exper. Ther. <u>262</u> :809-817 (Issue No. 2).
<i>He</i>	BW!	Lunde, I., 1990, "Antihistamines", Side Effects of Drugs <u>14</u> :135-138

	BX!	Dukes, M.N.G. et al., 1988, "Side Effects of Drugs Annual 12", Elsevier Science Publishers B.V. pp. 142-143
	BY	Ebert, W., 1977, "Soft Elastic Gelatin Capsules: A Unique Dosage Form", Pharmaceutical Technology 1:44-50 (October 1977).
EXAMINER L. E. Crane 		DATE CONSIDERED 06/09/99
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

! Month of publication data is unavailable for this reference.
 ** Copy of citation not supplied by applicant.

COPY FOR ☐ File ☐ Applicant

COPY FOR ☐ File ☐ Applicant